153P Molecular epidemiology of EGFR mutations in NSCLC: A single-center experience from India

EGFR (Epidermal growth factor receptor) is a key driver mutation frequently isolated in lung cancers and anti-EGFR TKIs (tyrosine kinase inhibitors) have demonstrated significant improvements patient outcomes comparison to conventional chemotherapy. This study assessed the prevalence clinical of mutations among Indian NSCLC cohort. Retrospective analysis 2548 patients who underwent mutational from 2013 2021 using amplified refractory system (ARMS)/Scorpion® real time polymerase chain reaction. Clinical data for 141 was obtained significance Kaplan-Meier chi-square method. sensitizing were detected 40.4% (1029/2548) cases with compound 7.8% (81/1029) cases. at higher females (p = 0.002) never-smokers < 0.001) Uncommon locoregional variation Exon 18 G719X (7.2%) been most TKI resistant exon 20 T790M (3.98%) other cohorts. Insertions (1.8%) which received approval targeted therapies observed 19 relationship regard brain metastasis 0.011). Patient follow-up treatment response (mutational load) monitored ctDNA (liquid biopsy) on ddPCR platform. mutated individuals had significantly longer median overall survival compared wild type (26 months vs 12 months, p –0.044). The provides insights into molecular epidemiology TKD spectrum India, reiterating its role as predictive marker NSCLC. Mutational pre-requisite test employed identify subcategories would benefit therapy addition identification resistance already therapy.